122 related articles for article (PubMed ID: 17671433)
1. The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance.
Thoma CR; Frew IJ; Krek W
Cell Cycle; 2007 Aug; 6(15):1809-13. PubMed ID: 17671433
[TBL] [Abstract][Full Text] [Related]
2. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network.
Thoma CR; Frew IJ; Hoerner CR; Montani M; Moch H; Krek W
Nat Cell Biol; 2007 May; 9(5):588-95. PubMed ID: 17450132
[TBL] [Abstract][Full Text] [Related]
3. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation.
Frew IJ; Thoma CR; Georgiev S; Minola A; Hitz M; Montani M; Moch H; Krek W
EMBO J; 2008 Jun; 27(12):1747-57. PubMed ID: 18497742
[TBL] [Abstract][Full Text] [Related]
4. Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.
Guinot A; Lehmann H; Wild PJ; Frew IJ
J Pathol; 2016 Jul; 239(3):365-73. PubMed ID: 27126173
[TBL] [Abstract][Full Text] [Related]
5. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein.
Esteban MA; Harten SK; Tran MG; Maxwell PH
J Am Soc Nephrol; 2006 Jul; 17(7):1801-6. PubMed ID: 16775032
[TBL] [Abstract][Full Text] [Related]
6. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
Kuehn EW; Walz G; Benzing T
Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
[TBL] [Abstract][Full Text] [Related]
7. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells.
Lutz MS; Burk RD
Cancer Res; 2006 Jul; 66(14):6903-7. PubMed ID: 16849532
[TBL] [Abstract][Full Text] [Related]
8. Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients.
Fabbri L; Dufies M; Lacas-Gervais S; Gardie B; Gad-Lapiteau S; Parola J; Nottet N; Meyenberg Cunha de Padua M; Contenti J; Borchiellini D; Ferrero JM; Leclercq NR; Ambrosetti D; Mograbi B; Richard S; Viotti J; Chamorey E; Sadaghianloo N; Rouleau M; Craigen WJ; Mari B; Clavel S; Pagès G; Pouysségur J; Bost F; Mazure NM
Theranostics; 2020; 10(6):2696-2713. PubMed ID: 32194829
[No Abstract] [Full Text] [Related]
9. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
Nyhan MJ; O'Sullivan GC; McKenna SL
Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
[TBL] [Abstract][Full Text] [Related]
10. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
11. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
12. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
13. Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia.
Schraml P; Frew IJ; Thoma CR; Boysen G; Struckmann K; Krek W; Moch H
Mod Pathol; 2009 Jan; 22(1):31-6. PubMed ID: 18660794
[TBL] [Abstract][Full Text] [Related]
14. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease.
Montani M; Heinimann K; von Teichman A; Rudolph T; Perren A; Moch H
Am J Surg Pathol; 2010 Jun; 34(6):806-15. PubMed ID: 20431476
[TBL] [Abstract][Full Text] [Related]
15. Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics.
Frew IJ; Smole Z; Thoma CR; Krek W
Eur J Cancer; 2013 Jul; 49(10):2433-40. PubMed ID: 23541568
[TBL] [Abstract][Full Text] [Related]
16. The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.
Lolkema MP; Mans DA; Snijckers CM; van Noort M; van Beest M; Voest EE; Giles RH
FEBS Lett; 2007 Oct; 581(24):4571-6. PubMed ID: 17825299
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
18. The multifaceted von Hippel-Lindau tumour suppressor protein.
Robinson CM; Ohh M
FEBS Lett; 2014 Aug; 588(16):2704-11. PubMed ID: 24583008
[TBL] [Abstract][Full Text] [Related]
19. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD
Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672
[TBL] [Abstract][Full Text] [Related]
20. The von hippel-lindau tumor suppressor protein: an update.
Kaelin WG
Methods Enzymol; 2007; 435():371-83. PubMed ID: 17998064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]